oral semaglutide covered by insurance Cheaper weight-loss pills are entering U.S. pharmacies—but affordability and access remain major concerns. Ikon Kim examines what the shift could mean for patients and the future of GLP-1 treatment. Read more Are Any Weight Loss Drugs

Aphaia Pharma Headquarters: Switzerland Technology: oral glucose formulation Lead candidate: APH-012 As disruptions in the guts natural responses to food intake are linked to metabolic diseases, such as obesity, Swiss biotech company Aphaia Pharma has come up with a way to restore these said natural responses, different from conventional obesity therapies like GLP-1 agonists

Glucagon-like peptide-1 receptor agonists, such as semaglutide, offer promising therapeutic options that not only target type 2 diabetes but also can positively influence mood

ka = 0.0373 /h

In this regard, it is noteworthy that a selective glucagon receptor antagonist increased hepatic fat in patients with T2D 23